Impact of pericardial fluid glucose level and computed tomography attenuation values on diagnosis of malignancy-related pericardial effusion

Takashi Nakamura, Mana Okune, Masakazu Yasuda, Heitaro Watanabe, Masafumi Ueno, Kenji Yamaji, Kazuki Mizutani, Takashi Kurita and Gaku Nakazawa*

Abstract

Background: We evaluated malignancy according to the characteristics of pericardial fluid in symptomatic Japanese patients undergoing pericardiocentesis and computed tomography (CT).

Methods: This was a retrospective, single-center, observational study of 125 symptomatic patients undergoing pericardiocentesis. The patients were classified into two groups: a malignancy group and a non-malignancy group, according to the primary disease and cytology of the pericardial effusion (PE). We compared the pericardial fluid sample and CT measurements between both groups.

Results: All patients were diagnosed as having exudative PE by Light’s criteria. PE with malignant cells was demonstrated in 76.8% of the malignancy group patients. Pericardial to serum lactate dehydrogenase (LDH) ratio > 0.6, as one of Light’s criteria, was associated with malignancy (p = 0.017). Lower serum brain natriuretic peptide (BNP) concentration was also associated with malignancy (BNP: 126.9 ± 89.8 pg/ml vs 409.2 ± 97.7 pg/ml, malignancy vs non-malignancy groups, respectively; p = 0.037). A significant difference was observed in pericardial fluid glucose level between the malignancy and non-malignancy groups (pericardial fluid glucose: 78.24 ± 48.29 mg/dl vs 98.41 ± 44.85, respectively; p = 0.048). Moreover, CT attenuation values (Hounsfield units (HU)) tended to be higher in the malignancy group vs the non-malignancy group (22.7 [interquartile range (IQR), 17.4–26.0] vs 17.4 [IQR, 13.7–26.4], respectively; p = 0.08). The sensitivity and specificity of pericardial fluid glucose level < 70 mg/dl and CT attenuation values > 20 HU were 40.9% and 89.6%, respectively, in the malignancy group. The positive- and negative predictive values of pericardial fluid glucose level < 70 mg/dl and CT attenuation values > 20 HU were 85.7% and 50.0%, respectively, in the malignancy group. Pericardial fluid glucose level < 70 mg/dl and CT attenuation values > 20 HU were cutoff values associated with malignancy (p = 0.012).

Conclusions: Lower pericardial fluid glucose level with higher CT attenuation values may suggest malignancy-related PE.

Keywords: Pericardial effusion, Pericardial fluid glucose level, Malignancy, CT attenuation values

*Correspondence: gnakazawa@med.kindai.ac.jp
Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama 589-8511, Japan

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
distribution, and volume, results from many diseases [1]. In patients with PE, the prevalence of malignancy or infection ranges from 15 to 50% [2, 3], and malignant PE can be diagnosed by cytology. In addition to imaging and pericardial fluid analysis, the clinical course of the underlying disease can contribute to the diagnosis of malignancy-related PE. In particular, large PE is a common manifestation in malignant disease, and patients with malignant PE have a poor prognosis because of advanced-disease stage [4, 5]. In cases without pre-existing cancer, malignancy must be excluded because PE may be the first manifestation of malignancy. Some studies reported PE attributed to unknown causes at a rate of 10%–20% [5, 6]. It may be difficult to diagnose malignant PE even if cytology or epicardial and pericardial biopsy are performed [7]. A previous study of pericardial fluid analysis showed that diseases with exudative PE had lower pericardial fluid glucose levels compared with diseases with transudative PE [8]. However, the relationship between malignancy-related PE and non-malignant PE evaluated using computed tomography (CT) to analyze the pericardial fluid is unknown. Therefore, we examined malignancy according to the characteristics of the pericardial fluid and CT measurements in patients with symptoms associated with PE undergoing pericardiocentesis.

Methods
Patients
We enrolled 125 consecutive symptomatic patients undergoing pericardiocentesis between April 2010 and April 2020 as a retrospective observational study in a single institution.

Twenty-eight patients without pericardial fluid sampling and CT data were excluded because of out-of-hospital cardiopulmonary arrest, Stanford type A aortic dissection, and blow-out rupture in acute myocardial infarction as an intra-procedural complication. All patients who did not undergo thoracic CT scans because of cardiac shock were diagnosed on echocardiography in the emergency room. Therefore, 97 patients were finally enrolled in this study. The patients were classified into two groups: a malignancy group and a non-malignancy group. The malignancy group consisted of patients with known existing malignancy or documented malignant cells in drained PE.

Blood samples and pericardial fluid samples
According to the patients’ medical records, blood samples were collected for routine care approximately 24 h after the first drainage. The following were evaluated in the drained pericardial fluid: pH, total protein, lactate dehydrogenase (LDH), albumin, glucose, adenosine deaminase (ADA), hyaluronic acid, hemoglobin (Hb), and hematocrit. Collected pericardial fluid was cytologically diagnosed with malignant cells or non-malignant cells by two pathologists. Pericardial fluid testing was performed in 88 patients, and cytological analysis was performed in 94 patients. Patients were diagnosed with exudative PE according to Light’s criteria, which constitute a pericardial fluid-to-serum total protein ratio > 0.5 and a pericardial fluid-to-serum LDH ratio > 0.6 or two-thirds of the upper limit of the normal (UNL) serum LDH value [9].

CT protocol and measurement
Non-enhanced CT scans before drainage were performed within 24 h of admission using a 64-multidetector CT scanner (Discovery HD 750; GE Healthcare, Milwaukee, WI, USA). Eighty-one patients were evaluated, with 5-mm slice thickness, gantry rotation speed of 350 ms, 64 × 0.625-mm collimation, tube voltage of 120 kV, and effective tube current of 325–750 mA. Axial images were transferred to an available workstation and analyzed using SYNAPSE VINCENT software (Fujifilm™ Co., Tokyo, Japan). The CT attenuation values in the PE were calculated and analyzed by SYNAPSE VINCENT [10]. In addition to a previous method that was determined by the region of interest (ROI), CT attenuation values and pericardial area were measured by plotting around the PE using a two-dimensional (2D) image analysis system in three axial view slices as follows: (1) upper slice: bifurcation of the pulmonary trunk, (2) middle slice: four-chamber heart view, and (3) lower slice: upper edge of the liver (Fig. 1) [11]. The average CT attenuation value from the three slices was calculated as Hounsfield units (HU).

Statistical analysis
Categorical variables were compared using the χ² test for proportions and the unpaired t-test or analysis of variance for continuous variables, as appropriate. The linearity of the relationship between two variables was assessed by linear regression analysis. Correlation analysis was performed with Pearson’s correlation coefficient. Parameters with non-normal distributions were analyzed using the Mann–Whitney U test. p < 0.05 was considered significant, and results are expressed as the mean ± standard deviation (SD). CT attenuation values were measured by two cardiologists, and interobserver agreement was evaluated. The cardiologists independently analyzed the images and discussed the CT measurements. Interobserver reliability was calculated as intraclass correlation coefficient, and interobserver agreement was calculated as the k coefficient. In the case of interobserver disagreement, we selected CT attenuation values that were close to the CT attenuation values measured by a third cardiologist. All analyses were performed using JMP version 11.0.
Results
Baseline clinical characteristics
The baseline characteristics of the 97 subjects are shown in Table 1; the majority were male and > 65 years of age. Approximately 10% of the patients had previously taken antiplatelet agents, but few patients had received prior anticoagulation therapy. The most frequent etiology in patients undergoing pericardiocentesis was malignant disease (58.8%), and among these patients, 59.6% had lung cancer (Table 2). Pericardial fluid with malignant cells: positive-cytology was demonstrated in 76.8% of the patients in the malignancy group.

Blood samples (Table 3)
No significant differences in serum C-reactive protein (CRP), total protein, LDH, albumin, glucose, and Hb were observed between the malignancy and non-malignancy groups. In contrast, estimated glomerular filtration rate (eGFR) was significantly higher in patients with vs without malignancy (60.56 ± 31.42 ml/min/1.73 m² vs 45.97 ± 29.08 ml/min/1.73 m², respectively; p = 0.024). Serum brain natriuretic peptide (BNP) levels were significantly lower in patients with vs without malignancy (126.89 ± 183.35 pg/ml vs 409.18 ± 868.67 pg/ml, respectively; p = 0.037).

Pericardial fluid samples, pericardial/serum ratio, Light’s criteria, and cytology (Table 3).
No significant differences in pericardial fluid pH levels, total protein, LDH, albumin, ADA, and hyaluronic acid were observed between the two groups. Pericardial fluid glucose levels were significantly lower in patients with vs without malignancy (78.24 ± 48.29 vs 98.41 ± 44.85, respectively; p = 0.048) (Fig. 2).
Malignant cells in the pericardial fluid were demonstrated in 76.8% of the patients in the malignancy group. All patients were diagnosed as having exudative PE by Light’s criteria. Of the three items in Light’s criteria, LDH ratio > 0.6 and pericardial LDH > 2/3 of the UNL were associated with malignancy (\(p = 0.017\) and \(p = 0.036\), respectively). The pericardial fluid-to-serum LDH ratios were significantly higher in patients with malignancy than in those without malignancy (5.23 ± 7.69 vs 2.59 ± 2.71, respectively; \(p = 0.047\)). The pericardial fluid-to-serum glucose ratios were significantly lower in patients with vs without malignancy (0.57 ± 0.34 vs 0.83 ± 0.45, respectively; \(p = 0.005\)) (Fig. 2).

**CT measurements**

The interobserver correlation for determining CT attenuation values indicated good agreement [interclass

## Table 2

| Malignancy                      | n = 57 |
|--------------------------------|-------|
| Lung cancer                    | 34 (59.6) |
| Gastrointestinal carcinoma     | 7 (12.3) |
| Malignant lymphoma             | 3 (5.3) |
| Renal carcinoma                | 3 (5.3) |
| Breast carcinoma               | 2 (3.5) |
| Gynecological carcinoma        | 2 (3.5) |
| Pleural mesothelioma           | 1 (1.8) |
| Hemangiosarcoma                | 1 (1.8) |
| Primary cancer of unknown type  | 4 (7.0) |

## Table 3

| Serum component | Malignancy group | Non-malignancy group | \(p\)  |
|-----------------|------------------|----------------------|-------|
| CRP (mg/dl)     | 5.33 ± 4.37      | 4.54 ± 6.70          | 0.488 |
| eGFR (ml/min/1.73 m²) | 60.56 ± 31.42 | 45.97 ± 29.08       | 0.024 |
| Total protein (g/dl) | 6.08 ± 0.60  | 6.06 ± 1.27          | 0.889 |
| LDH (U/L)       | 543.35 ± 767.60  | 357.98 ± 186.54     | 0.138 |
| Albumin (g/dl)  | 3.01 ± 0.46      | 3.11 ± 0.75          | 0.399 |
| Glucose (mg/dl) | 142.20 ± 61.03   | 134.10 ± 53.05      | 0.518 |
| Hemoglobin (g/dl)| 11.01 ± 1.77    | 11.11 ± 1.60        | 0.766 |
| Hematocrit (%)  | 33.29 ± 5.61     | 34.24 ± 4.84        | 0.391 |
| BNP (pg/ml)     | 126.89 ± 183.35  | 409.18 ± 868.67     | 0.037 |

| Pericardial fluid component                          | Malignancy group | Non-malignancy group | \(p\)  |
|------------------------------------------------------|------------------|----------------------|-------|
| Ph                                                   | 7.39 ± 0.20      | 7.48 ± 0.12          | 0.069 |
| Total protein (g/dl)                                | 5.02 ± 0.80      | 4.72 ± 1.19          | 0.166 |
| LDH (U/L)                                           | 2032.10 ± 3522.33 | 1029.58 ± 1561.52 | 0.106 |
| Albumin (g/dl)                                      | 2.66 ± 0.53      | 2.61 ± 0.70          | 0.661 |
| Glucose (mg/dl)                                     | 78.24 ± 48.29    | 98.41 ± 44.85       | 0.048 |
| ADA (U/L)                                           | 37.59 ± 47.26    | 29.34 ± 37.66       | 0.389 |
| Hyaluronic acid (ng/ml)                             | 31.975.9 ± 27,282.7 | 27.194.5 ± 28,745.9 | 0.438 |
| Hemoglobin (g/dl)                                   | 3.83 ± 2.22      | 5.15 ± 5.19         | 0.422 |
| Hematocrit (%)                                      | 14.79 ± 6.73     | 16.74 ± 21.36       | 0.788 |

| Variable                                             | Malignancy group | Non-malignancy group | \(p\)  |
|------------------------------------------------------|------------------|----------------------|-------|
| Total protein ratio                                 | 0.83 ± 0.14      | 0.78 ± 0.15          | 0.127 |
| LDH ratio                                           | 5.23 ± 7.69      | 2.59 ± 2.71          | 0.047 |
| Glucose ratio                                       | 0.57 ± 0.34      | 0.83 ± 0.45          | 0.005 |
| Pericardial fluid/Serum total protein ratio > 0.5   | 49 (100%)        | 38 (97.4%)           | 0.260 |
| Pericardial fluid/Serum LDH ratio > 0.6             | 47 (94.0%)       | 29 (76.3%)           | 0.017 |
| Pericardial fluid LDH > 2/3 UNL                     | 49 (98.0%)       | 32 (86.5%)           | 0.036 |
| Cytology, positive                                  | 43 (76.8%)       | —                    | —     |

Lower serum BNP and lower pericardial fluid glucose level were associated with malignancy

Values are expressed as mean ± standard deviation

CRP C-reactive protein, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase, BNP brain natriuretic protein, ADA adenosine deaminase, UNL upper limit of normal
correlation coefficient, 0.965 (95% confidence interval (CI), 0.946–0.977)]. The interobserver agreement for determining CT attenuation values also indicated good agreement [κ coefficient, 0.82].

CT attenuation values (HU) tended to be higher in the malignancy group compared with the non-malignancy group (22.7 [interquartile range (IQR), 17.4–26.0] vs 17.4 [IQR, 13.7–26.4], respectively). However, the p-value was 0.08; therefore, no significant difference in CT attenuation values was observed between the malignancy and non-malignancy groups. In contrast, CT attenuation values > 20 HU were associated with malignancy ($p = 0.006$) (Fig. 3).

The relationship between pericardial fluid samples and CT measurements.

The relationship between pericardial fluid measurements and CT attenuation values is shown in Fig. 4. CT attenuation values were strongly correlated with pericardial fluid hematocrit ($r = 0.908$). CT attenuation values were also correlated with pericardial fluid glucose level ($r = -0.425$), protein level ($r = 0.541$), glucose ratio ($r = -0.461$), and protein ratio ($r = 0.583$). The sensitivity and specificity of pericardial fluid glucose level ≤ 70 mg/dl and CT attenuation values > 20 HU were 40.9% and 89.6%, respectively, in the malignancy group. The positive- and negative predictive values of pericardial fluid glucose level ≤ 70 mg/dl and CT attenuation values > 20 HU were 85.7% and 50.0%, respectively, in the malignancy group. Pericardial fluid glucose ≤ 70 mg/dl and CT attenuation values > 20 HU were cutoff values associated with malignancy (Fig. 5). Additionally, pericardial fluid glucose ≤ 70 mg/dl and CT attenuation values > 20 HU were also cutoff values associated with positive-cytology patients (see Additional file 1: Fig. S1).

Discussion

To the best of our knowledge, the current study is the first to investigate malignancy-related PE by adding the characteristics of CT images to the pericardial fluid examination. We found that lower pericardial fluid glucose level and higher CT attenuation values were related to PE owing to malignancy. In particular, pericardial fluid analysis in patients undergoing pericardiocentesis is performed routinely, but the results of this analysis are not effectively used in clinical practice.

Malignant PE is a serious manifestation associated with a poor prognosis [4, 5]. However, PE may be the first manifestation of malignancy in some cases without pre-existing cancer; therefore, malignant PE must be considered, even if the cytology is negative. In the current study, the combination of lower pericardial fluid glucose level and higher CT attenuation values was a useful tool for differentiating malignancy-related PE from non-malignancy-related PE.

Strobbe et al. evaluated the etiologies of PE and distinguished radiation therapy for malignancy as a cause of PE [12]. Moreover, the authors reported that bone marrow transplantation was an etiology in the idiopathic group [12]. Additionally, Sullivan et al. reported that chronic graft-versus-host disease (GVHD) presented as an immune reaction after bone marrow transplantation, similar to the mechanism in autoimmune diseases [13]. Therefore, non-recurrent cancer patients with prior radiation therapy or chronic GVHD were included in our non-malignancy group.

In the current study, the number of patients in the malignancy group was higher than the number in the non-malignancy group, and approximately 60% of the patients in the malignancy group had lung cancer. While the percentage of patients with an idiopathic etiology in our study was 7.2%, one study in Western Asia and...
another in Africa reported PE attributed to unknown causes at rates of approximately 10%–15% [6, 14]. In contrast, a study in Western Europe and another in North America reported that approximately 80%–90% of patients with PE were classified as having an idiopathic etiology [2, 15]. Distinguishing malignant PE from non-malignant PE has important implications regarding prognosis. However, two previous studies reported that 44.9%–92% of patients with malignancy often demonstrated malignant cells in PE [8, 16]. As a result of cytology by repeat drainage, the current study showed that 76.8% of patients in the malignancy group demonstrated malignant cells in the pericardial fluid. Standard pericardial cytology does not necessarily exclude malignant PE; therefore, it is necessary to detect neoplasia using blood samples, pericardial fluid analysis, and imaging modalities, such as positron-emission tomography-CT (PET-CT). Cytology-negative patients in the malignancy group in this study were defined as patients who had untreatable recurrent or metastatic carcinoma.

Although pericardial fluid analysis is performed routinely, the results of this analysis are not effectively used owing to a lack of specificity. Meyers et al. reported that pericardial fluid glucose level was lower in patients with exudates than in those with transudates, and there was a significant overlap in the etiology of PE between patients with transudates vs exudates [8]. All cases in our study, in both the malignancy and non-malignancy groups, were diagnosed as having exudative PE by Light’s criteria. No significant differences in pericardial fluid LDH levels were observed between the groups, while LDH ratio > 0.6 and pericardial LDH > 2/3 of the UNL were associated with malignancy. Ben-Horin et al. demonstrated pericardial fluid LDH level > 2.4 times the serum level and mean pericardial fluid protein level 0.6 times the serum level in patients undergoing elective open surgery without a history of pericardial diseases [17]. Despite these findings, a recent study showed that patients with malignancy had lower PE LDH levels than patients without malignancy, and another study showed that malignant patients had lower PE glucose levels compared with
Fig. 4 Correlation between CT attenuation values and pericardial fluid parameters. The pericardial fluid parameters were: total protein level, protein ratio, glucose level, glucose ratio, hematocrit, and hemoglobin. Each dot represents one patient; the straight line represents the best fit line obtained by linear regression analysis. Pf: pericardial fluid, Se: serum, HU: Hounsfield units, CT: computed tomography.

Fig. 5 Relationship between pericardial fluid glucose or CT attenuation values and malignancy vs non-malignancy. Pericardial fluid glucose ≤ 70 mg/dl and CT attenuation values > 20 HU were cutoff values associated with malignancy. Pf: pericardial fluid, CT: computed tomography.
patients with heart failure-related effusion [16, 18]. Furthermore, Ben-Horin et al. demonstrated a mean pericardial fluid glucose level of 133 mg/dl and mean pericardial fluid-to-serum glucose ratio of 1.0 in patients without a history of pericardial diseases [17]. In the current study, pericardial fluid glucose levels and pericardial fluid-to-serum glucose ratio were significantly lower in the malignancy group than in the non-malignancy group. In an additional analysis, pericardial fluid glucose levels were significantly lower in positive-cytology patients than in negative-cytology patients. However, neither pericardial fluid glucose levels nor the pericardial fluid-to-serum glucose ratio in our study was helpful for differentiating the malignancy group from the non-malignancy group because the areas under the receiver operating characteristic (ROC) curve were <0.7. Based on these results, the cutoff value for pericardial fluid glucose level under the ROC curve for differentiating the malignancy group from the non-malignancy group was 70 mg/dl. Pericardial fluid glucose level may decrease in diseases such as tuberculosis, rheumatism, and inflammatory diseases in non-malignancy patients, and serum glucose level can change secondary to various factors. The results of Gram’s stain and acid-fast bacteria stain of pericardial fluid were negative in this study. Additionally, no significant differences in the rates of diabetes mellitus and hypoglycemic agents were observed between the groups regarding pericardial fluid glucose levels. In contrast, CT attenuation values may be useful in determining the etiology of PE. We measured CT attenuation values in PE areas larger than the area in the ROI and used the former as the CT attenuation value. Previous studies reported that CT attenuation values were positively correlated with pleural and pericardial total protein levels and the pleural and pericardial/serum protein ratio [11, 19]. Moreover, Rifkin et al. demonstrated that CT attenuation values were strongly correlated with pericardial fluid hematocrit [20]. Our study showed that CT attenuation values were strongly correlated with pericardial fluid hematocrit, and that these values also had a good correlation with pericardial fluid glucose and protein levels, and glucose ratio and protein ratio. CT attenuation values from 20 to 60 HU indicated exudate in hypothyroidism, purulent pericarditis, or malignancy [21]. The median CT attenuation values in both groups was >20 HU for exudates, while the cutoff value was determined to be 20 HU according to a previous report indicating that patients with CT attenuation values >20 HU had proteinaceous or hemorrhagic PE [22]. In the current study, the cutoff value for CT attenuation under the ROC curve for differentiating the malignancy group from the non-malignancy group was 19.7 HU; approximately 20 HU. As a result, CT attenuation values >20 HU were associated with malignancy.

In our study, PE for differentiating the malignancy group from the non-malignancy group was evaluated by the combination of pericardial fluid glucose level and CT attenuation values. Pericardial fluid glucose level ≤70 mg/dl and CT attenuation values >20 HU had 40.9% sensitivity and 89.6% specificity for discriminating the malignancy group from the non-malignancy group. Additionally, our study demonstrated that CT attenuation values had a good correlation with pericardial fluid glucose level. According to our results, the combination of pericardial fluid glucose ≤70 mg/dl and CT attenuation values >20 HU might be associated with malignancy in PE. In addition, this study showed that this combination was associated with positive-cytology patients.

Recent studies showed that pericarditis related to malignancy, except for pericardial infiltration of malignant cells and radiation therapy, was associated with antineoplastic agents, such as tyrosine kinase inhibitors and immune checkpoint inhibitors [23, 24]. Although we attempted to exclude PE related to antineoplastic agents, it was difficult to demonstrate the effect of these therapies in negative-cytology patients in the malignancy group because this was a diagnosis of exclusion. In future, we must pay attention to antineoplastic agent use in patients with malignancy and PE.

The strength of this study is that we evaluated diagnostic procedures that are readily available in clinical practice. Pericardial fluid analysis and CT imaging are simple and routine tools to diagnose malignancy-related PE. Pericardial fluid glucose level and CT attenuation values can be obtained quickly; therefore, this effective method should be used in clinical practice.

Study limitations
There are several limitations to our study. First, the size of the non-malignancy group was small because this was a single-institution study. Second, the malignancy group had higher proportions of patients with lung cancer. The retrospective nature of this study is another limitation.

Conclusions
Lower pericardial fluid glucose level in addition to higher CT attenuation values may suggest malignancy-related PE. In patients with pericardial fluid glucose ≤70 mg/dl and CT attenuation values >20 HU, malignant disease as the cause of PE must be excluded by other examinations and imaging modalities, even if there are no malignant cells in pericardial fluid cytology.
Abbreviations
CT: Computed tomography; PE: Pericardial effusion; LDH: Lactate dehydrogenase; BNP: Brain natriuretic peptide; HU: Hounsfield units; IQR: Interquartile range; ADA: Adenosine deaminase; UNL: Upper limit of normal; ROI: Region of interest; 2D: Two-dimensional; CRP: C-reaction protein; Hb: Hemoglobin; eGFR: Estimated glomerular filtration rate; PET-CT: Positron-emission tomography-CT; ROC: Receiver operating characteristic.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-02091-6.

Additional file 1: Fig. S1. Relationship between pericardial fluid glucose or CT attenuation values and positive cytology/ys negative cytology. Pericardial fluid glucose ≤ 70 mg/dl and CT attenuation values > 20 HU were cutoff values associated with positive cytology. P: pericardial fluid, CT computed tomography.

Acknowledgements
We thank Jane Charbonneau, DVM, from Edanz Group (https://jiedanz.com/ac) for editing a draft of this manuscript.

Authors’ contributions
TN: research concept or design, data collection, writing the manuscript; MO: data collection, approval of the final draft; MY, HW, MJ, KY, KM: data analysis and interpretation, approval of the final draft; GN: research concept or design, significant revision of the manuscript, approval of the final draft. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Kindai University Hospital. This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by our institution’s human research committee. This was a retrospective observational study, with need to obtain informed consent was waived by the Ethics Committee of Kindai University Hospital. This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by our institution’s human research committee. This was a retrospective observational study, with need to obtain informed consent was waived by the Ethics Committee of Kindai University Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 25 February 2021 Accepted: 27 May 2021
Published online: 03 June 2021

References
1. Aday Y, Charron P, Irazoqui M, Badano L, Barón-Esfagias G, Bogaert J, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921–64.
2. Irazoqui M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916–28.
3. Irazoqui M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115:2739–44.
4. El Haddad D, Iliescu C, Yusuf SW, William WN Jr, Khair TH, Song J, et al. Outcomes of cancer patients undergoing percutaneous pericardiotensis for pericardial effusion. J Am Coll Cardiol. 2015;66:1119–28.
5. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol. 2005;23:5211–6.
6. Albuguami S, Al-Husayni F, AAlmalki A, Dumyati M, Zakri Y, AlRahimi J. Endomyocardial biopsy for the diagnosis of pericardial effusion and outcomes post pericardiotensis in the western region of Saudi Arabia: a single-center experience. Cureus. 2020;12:e6627.
7. Burazor I, Irazoqui M, Markel G, Adler Y. Malignant pericardial effusion. Cardioiology. 2013;124:224–32.
8. Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. Chest. 1997;111:1213–21.
9. Akyuz S, Arugaslan E, Zengin A, Onuk T, Ceylan US, Yaylak B, et al. Differentiation between transudate and exudate in pericardial effusion has almost no diagnostic value in contemporary medicine. Clin Lab. 2015;61:957–63. https://doi.org/10.7754/clin.lab.2015.150114.
10. Sogawa N, Michiu T, Kawamoto O, Orihito S, Ishikawa T, Maeda H. Postmortem virtual volumetry of the heart and lung in situ using CT data for investigating terminal cardiopulmonary pathophysiology in forensic autopsies. Leg Med. Med (Tokyo). 2014;16:187–92.
11. Çetin MS, Özcan Çetin EH, Ozdemir M, Topaloğlu S, Aras D, Temizhan A, et al. Effectiveness of computed tomography attenuation values in characterization of pericardial effusion. Anatol J Cardiol. 2017;17:322–7.
12. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, et al. Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am Heart Assoc. 2017;6:e007598.
13. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RR, McDonal GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immuno-suppression. Blood. 1981;57:267–76.
14. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart. 2007;93:1176–83.
15. LeWinter MM. Clinical practice: acute pericarditis. N Engl J Med. 2014;371:2401–6.
16. Cheong XP, Law LKP, Seow SC, Tay LWE, Tan HC, Yeo WT, et al. Causes and prognosis of symptomatic pericardial effusions treated by pericardiocentesis in an Asian academic medical centre. Singapore Med J. 2010;51:137–41.
17. Ben-Horin S, Shinfeld A, Kachel E, Chetrit A, Livneh A. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. Am J Med. 2005;118:636–40.
18. Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev. 2013;18:337–44.
19. Nandalar KR, Hardie AH, Bollampally SR, Parmar JP, Hagspiel KD. Accuracy of computed tomography attenuation values in the characterization of pleural fluid: an ROC study. Acad Radiol. 2005;12:987–91.
20. Rifkin RD, Mernoff DB. Noninvasive evaluation of pericardial effusion composition by computed tomography. Am Heart J. 2005;149:1120–7.
21. O’Leary SM, Williams PL, Williams MP, Edwards AJ, Roobottom CA, Morgan-Hughes GJ, et al. Imaging the pericardium: appearances on ECG-gated 64-detector row cardiac computed tomography. Br J Radiol. 2010;83:194–205.
22. Verhaert D, Gabriel RS, Johnston D, Lytle BW, Desai MY, Klein AL. The role of multimodality imaging in the management of pericardial disease. Circ Cardiovasc Imaging. 2010;3:333–43.
23. Shnider SH, Ha JE, Zang DY, Kim SH, Do YR, Lee WS, et al. Appropriate starting dose of dasatinib based on analyses of dose-limiting toxicities and
molecular responses in Asian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2021;52152–2650(21):00038.

24. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, et al. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol. 2019;123:1351–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.